Genmab — April 2017
-
Enig Solsen.
-
Darzalex vs. Emplicit - Sellside consensus. https://twitter.com/JacobPlieth/status/852459600272138240
-
http://epvantage.com/Universal/View.aspx?type=Story&id=700608&isEPVantage=yes Artikelen grafen er fra, der er også en fin timeline over readout på de vigtige dara
studier -
Tak for link Budweiss og Mads.
-
Alligevel har der indsneget sig en lille fejl i artiklen. Cassiopeia er ikke i kombi med Revlimid men Thalidomid. Hvis effekten er god, kan det have en betydelig prismæssig betydning, da patentet på Thalidomid udløber allerede i 2018 https://www.drugs.com/availability/generic-thalomid.html . Længe inden Cassiopeia er færdigt.
-
Har ikke adgang, men mon ikke Jan er meget fortrøstningsfuld? http://www.proinvestor.com/r.php?u=http%3A%2F%2Fmedwatch.dk%2FMedicinal___Biotek%2Farticle9508531.ece%3Futm_source%3DFeed%26amp%3Butm_medium%3Dlatest
-
Se under nyheder "Genmab-topchef: Godkendelse kan fordoble Darzalexs marked_Markedet for Darzalex vil blive fordoblet, hvis midlet bliver godkendt som standardbehandlingsmiddel mod knoglemarvskræft. Det vurderer CEO Jan van de Winkel over for Berlingske Business...."
-
BMS i nyt samarbejde
http://medwatch.dk/secure/Medicinal___Biotek
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind